HPV vaccine, imiquimod, and metformin for advanced cervical or vulvar cancer
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This trial tests a combination of an HPV vaccine, an immune cream (imiquimod), and a diabetes drug (metformin) together with standard chemoradiation. The goal is to see if this mix helps treat advanced cervical, vaginal, or vulvar cancers better than standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical, vaginal, or vulvar cancer that is locally advanced or has spread, and surgery is not the first option
- You are newly diagnosed and have not yet received other investigational treatments
- You are generally able to take care of yourself (ECOG performance status 0–2)
- You are 18 years or older
- Your blood counts, kidney, and liver function are within acceptable ranges, checked within a month before starting
- You are not pregnant and agree not to breastfeed during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy (with or without an anti-VEGF drug) followed by standard chemoradiation for women with advanced cervical cancer that hasn't spread beyond the pelvis. It aims to see if this approach can shrink tumors more effectively than standard treatment alone.
This trial tests a new treatment using your own immune cells (called T cells) that are modified to target HPV-positive cancer cells. It may be an option if you have advanced cervical, head/neck, anal, penile, vulvar, or vaginal cancer that is HPV16 or HPV52 positive and has progressed after standard therapy.
This trial tests combining two drugs, nivolumab (an immunotherapy) and imiquimod (a cream that boosts the immune system), to treat vulvar squamous cell carcinoma. It aims to shrink tumors before surgery and may be an option for women with large or multifocal tumors.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a combination of an immunotherapy drug (QL1706) and a nine-strain HPV vaccine as a first treatment for cervical cancer that has come back, spread, or persists. It aims to see if this approach can help people with persistent, recurrent, or metastatic cervical cancer who have not had prior systemic therapy.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
Hear when a new Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.